. 2018 Nov 15;10(11):398–409. doi: 10.4251/wjgo.v10.i11.398

Table 2.

Overall survival and median survival time

Reference	Years	OS (rate)			MST (mo)
		CHT	CHT + surgery		CHT	CHT + surgery
			R1/R2	R0		R1/R2	R0
Nakajima et al[73], 1997	2/3-yr				4.7	6.5
Nakajima et al[73], 1997	5-yr			55.6	4.7	6.5
Yano et al[74], 2002²	2/3-yr
Yano et al[74], 2002²	5-yr
Satoh et al[75], 2012	2/3-yr		43	75¹			19.2
Satoh et al[75], 2012	5-yr						19.2
Kanda et al[76], 2012	2/3-yr		0	45.9			29
Kanda et al[76], 2012	5-yr			34.4			29
Han et al[77], 2014	2/3-yr			41.4		7.8	22.9
Han et al[77], 2014	5-yr					7.8	22.9
Kim et al[78], 2014	2/3-yr	0	0	50	8	18	37
Kim et al[78], 2014	5-yr				8	18	37
Fukuchi et al[79], 2015	2/3-yr				14	30	62
Fukuchi et al[79], 2015	5-yr	1	15	49	14	30	62
Kinoshita et al[80], 2015	2/3-yr	0	16	63.5	9.6	29.9
Kinoshita et al[80], 2015	5-yr				9.6	29.9
Sato et al[81], 2017	2/3-yr	18.7			15.7	21.7	47.9
Sato et al[81], 2017	5-yr	0	0	48.6	15.7	21.7	47.9
Einama et al[82], 2017	2/3-yr						29
Einama et al[82], 2017	5-yr						29
Mieno et al[83], 2017	2/3-yr	56.9		73.1		56.1
Mieno et al[83], 2017	5-yr					56.1
Yamaguchi et al[84], 2017	2/3-yr				11.3	21.2	41.3
Yamaguchi et al[84], 2017	5-yr				11.3	21.2	41.3
Morgagni et al[85], 2018	2/3 yr	0		39.4	14		38³
Morgagni et al[85], 2018	5 yr				14		38³

R0 in only pre-Cy1 patients;

No data are specified but a P value < 0.0003 is shown between resected and not-resected 5-years OS rate;

Patients who had cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had an MST of 50 mo. OS: Overall survival; MST: Median survival time; CHT: Chemotherapy.